🕷️
SetupAI
繁
🐯Freshcollected in 26m

Personalized mRNA Cancer Vaccine Clears Phase 3 Hurdle

Personalized mRNA Cancer Vaccine Clears Phase 3 Hurdle
PostLinkedIn
🐯Read original on 虎嗅
#cancer-vaccine#neoantigens#clinical-trial#precision-medicinemrna-4157modernamerckmrna-4157pembrolizumabbiontech

💡A 1,137-patient Phase 3 result gives personalized mRNA oncology its strongest clinical validation yet.

⚡ 30-Second TL;DR

What Changed

The randomized global Phase 3 trial enrolled 1,137 patients and compared combination therapy with pembrolizumab alone.

Why It Matters

This is an important validation signal for personalized mRNA oncology and could accelerate investment in tumor sequencing, antigen prediction, and individualized manufacturing. However, the result comes from a relatively immunogenic cancer type, so performance across other cancers remains uncertain.

What To Do Next

Prototype a neoantigen-ranking workflow on public tumor-sequencing datasets, but benchmark its predictions against validated immunogenicity data before considering clinical use.

Who should care:Researchers & Academics

Key Points

  • •The randomized global Phase 3 trial enrolled 1,137 patients and compared combination therapy with pembrolizumab alone.
  • •Interim analysis showed statistically significant and clinically meaningful improvements in recurrence-free and distant metastasis-free survival.
  • •mRNA-4157 is a personalized vaccine designed from each patient’s tumor mutations and encodes 34 selected neoantigens.
  • •The platform is also being studied in non-small cell lung cancer, bladder cancer, and renal cell carcinoma.

🧠 Deep Insight

Background and context from public sources — not the original article. 31 sources cited.

🔑 Enhanced Key Takeaways

  • •The personalized mRNA cancer vaccine, also known as V940 and intismeran autogene, is being jointly developed by Merck and Moderna, with both companies sharing costs and profits equally under a worldwide collaboration.
  • •Five-year follow-up data from the Phase 2b KEYNOTE-942 trial demonstrated a sustained 49% reduction in the risk of recurrence or death and a 59% reduction in the risk of distant metastasis or death when mRNA-4157 was combined with pembrolizumab, compared to pembrolizumab alone.
  • •The vaccine's design process involves whole-exome sequencing (WES) and RNA sequencing (RNA-seq) of a patient's tumor and blood samples, followed by an automated algorithm to select up to 34 neoantigens.
  • •mRNA-4157/V940 received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) in February 2023, based on the promising Phase 2b results.
  • •The Phase 3 INTerpath-001 trial marks the first positive late-stage trial result for an mRNA-based cancer treatment and an individualized neoantigen therapy, signifying a landmark moment in cancer care.
📊 Competitor Analysis▸ Show
Company/CollaborationProduct/PlatformKey FeaturesTarget Cancers (Clinical Stage)Latest Benchmarks/Results (if available)
Moderna & MerckmRNA-4157 (V940) / Intismeran AutogenePersonalized mRNA vaccine, targets up to 34 neoantigens, combined with PD-1 inhibitor (Keytruda)Melanoma (Phase 3 positive), NSCLC (Phase 3), Bladder, Renal Cell Carcinoma (Phase 2), Pancreatic, Gastric (Phase 1)Phase 3: Statistically significant and clinically meaningful improvements in recurrence-free and distant metastasis-free survival in high-risk melanoma. Phase 2b (5-year follow-up): 49% reduction in recurrence/death risk, 59% reduction in distant metastasis/death risk in high-risk melanoma.
BioNTech (with Genentech/Roche)iNeST (individualized Neoantigen Specific Immunotherapy) / Autogene CevumeranPersonalized mRNA vaccine, integrates tumor sequencing, antigen prediction, and personalized vaccine designMelanoma, Head and Neck Cancers, NSCLC, Pancreatic Cancer, Colorectal Cancer (Phase 2)Memorial Sloan Kettering collaboration showed nearly 90% of pancreatic cancer patients whose immune systems responded to personalized mRNA vaccine were alive up to six years.
Gritstone bioGRANITEPersonalized self-amplifying mRNA (saRNA) neoantigen vaccine, also uses adenoviral vectorsColorectal Cancer (Phase 2/3), Advanced Metastatic Cancers (Phase 1)Phase 2 for colorectal cancer missed primary endpoint (ctDNA response), but showed an early trend toward benefit in progression-free survival in high-risk patients.
Agenus Inc.ASV® platformIndividualized vaccine platform targeting unique antigens in a patient's tumorVarious cancers (details not specified in search results)Details not publicly available for comparison.
Dana-Farber Cancer InstituteNeoVaxPersonalized peptide vaccine, identifies up to 20 mutant proteins (neoantigens)Advanced Melanoma (Clinical Trials)Safe, well-tolerated, long-lasting anti-tumor immune response and tumor control (around 4 years).

🛠️ Technical Deep Dive

  • mRNA-4157 (V940) is an individualized neoantigen therapy (INT) consisting of a single synthetic mRNA molecule.
  • It encodes for up to 34 patient-specific neoantigens, which are unique mutations present in an individual patient's tumor.
  • The design process involves analyzing the patient's tumor and healthy genes through whole-exome sequencing (WES) and RNA sequencing (RNA-seq) to identify these unique mutational signatures.
  • An automated algorithm is used to select the most immunogenic neoantigens for inclusion in the vaccine.
  • The mRNA sequences are encapsulated in solid lipid nanoparticles (LNPs) for stable delivery into the body.
  • Upon administration (intramuscular injection), the RNA-encoded neoantigen sequences are translated endogenously, undergo natural cellular antigen processing and presentation, which is intended to elicit a specific T-cell immune response against cancer cells.
  • The vaccine is designed to work in combination with pembrolizumab (Keytruda), where the vaccine trains the immune system to recognize tumor mutations, and Keytruda helps release the immune system's 'brakes' to enhance the attack.

🔮 Future ImplicationsAI analysis grounded in cited sources

Regulatory approval for mRNA-4157/V940 in high-risk melanoma is highly probable in the near future.
The positive Phase 3 results, coupled with prior Breakthrough Therapy Designation and sustained efficacy shown in Phase 2b, strongly position the therapy for regulatory submission and approval.
The success of mRNA-4157/V940 will significantly accelerate research and investment in personalized mRNA cancer vaccines across a broader range of malignancies.
This landmark Phase 3 success provides crucial validation for the personalized mRNA neoantigen vaccine platform, encouraging its application and development in other difficult-to-treat cancers.
Personalized neoantigen therapies could become a new standard of care for adjuvant treatment in various high-risk resected cancers.
The demonstrated ability to significantly reduce recurrence and distant metastasis after surgery suggests a paradigm shift towards more precise, individualized approaches to prevent cancer relapse.

⏳ Timeline

2016-06
Merck and Moderna announce strategic collaboration to develop mRNA-based personalized cancer vaccines.
2017
Moderna begins initial development of mRNA-4157/V940.
2019
Moderna and Merck jointly initiate clinical trials for mRNA-4157/V940 in combination with pembrolizumab for resected stage IIIB-IV melanoma.
2022-12
Phase 2b KEYNOTE-942 trial meets its primary endpoint, showing a 44% reduction in the risk of recurrence or death in high-risk melanoma.
2023-02
U.S. FDA grants mRNA-4157/V940 Breakthrough Therapy Designation.
2026-08
Phase 3 INTerpath-001 trial meets primary and key secondary endpoints in high-risk melanoma, showing significant improvements in recurrence-free and distant metastasis-free survival.
🐯Read original article on 虎嗅
📰

Weekly AI Recap

Read this week's curated digest of top AI events →

👉Related Updates

Same topic

Explore #cancer-vaccine

Same product

More on mrna-4157

Same source

Latest from 虎嗅

AI Maps China’s New Urban Industry Playbook

AI Maps China’s New Urban Industry Playbook

虎嗅•Aug 20
🐯

Duan Yongping Tests Alibaba Again

虎嗅•Aug 20
Nvidia Pushes CPO Into AI Factories

Nvidia Pushes CPO Into AI Factories

虎嗅•Aug 20
AI巨頭開始與美國財政部搶錢

AI巨頭開始與美國財政部搶錢

虎嗅•Aug 20

AI-curated news aggregator. All content rights belong to original publishers.
Original source: 虎嗅 ↗

This is a summary, not the original. Read the source, or get the weekly briefing.

Weekly AI briefing

One email a week. Unsubscribe anytime.